ITI will be attending SITC 2022 in Boston, MA The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance ...
BIO is thrilled to be back in person for the 2022 International Convention happening in San Diego, CA June 13-16. The Convention theme ‘LIMITLESS’ is our commitment to unlocking possibilities for our ...
ITI will be virtually attending The 40th Annual Health Care Conference that will take place on January 10-13, 2022 at the Westin St. Francis in San Francisco, CA. This premier ...
ITI will be attending the 2nd International Symposium on Merkel Cell Carcinoma. The focus of this symposium is to explore emerging data that may allow improvements in clinical guidelines, develop ...
2022 BIO CEO & Investor Conference: Hybrid Event ITI will be presenting at BIO CEO & Investor Conference virtually, stay tuned for more details. For more than 20 years, the ...
ITI Announces Open Enrollment for RENEW Clinical Study for the Treatment of Newly-Diagnosed Glioblastoma Patients
November 30, 2021 02:01 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the opening ...
- Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors November 23, 2021 06:41 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology ...
ITI Presents Clinical Data From ATTAC Studies in GBM at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting
November 18, 2021 ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D. ...
July 27, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today ...
July 21, 2021 10:35 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today ...
Biotech leader joins team as company evolves investigational UNITE platform and advances business July 19, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical ...
Click below to view ITI's abstract, titled, "Development and Characterization of a HCMV multiantigen therapeutic vaccine for GBM using the UNITE platform, published by ASCO, May 18, 2021: Meeting Library ...